Tvardi Therapeutics (TVRD) Competitors $5.00 -0.16 (-3.10%) As of 03:39 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TVRD vs. CRBU, OGI, LFCR, ALTS, AVIR, SGMT, CRBP, HRTX, ENTA, and RNACShould you be buying Tvardi Therapeutics stock or one of its competitors? The main competitors of Tvardi Therapeutics include Caribou Biosciences (CRBU), Organigram Global (OGI), Lifecore Biomedical (LFCR), ALT5 Sigma (ALTS), Atea Pharmaceuticals (AVIR), Sagimet Biosciences (SGMT), Corbus Pharmaceuticals (CRBP), Heron Therapeutics (HRTX), Enanta Pharmaceuticals (ENTA), and Cartesian Therapeutics (RNAC). These companies are all part of the "pharmaceutical products" industry. Tvardi Therapeutics vs. Its Competitors Caribou Biosciences Organigram Global Lifecore Biomedical ALT5 Sigma Atea Pharmaceuticals Sagimet Biosciences Corbus Pharmaceuticals Heron Therapeutics Enanta Pharmaceuticals Cartesian Therapeutics Caribou Biosciences (NASDAQ:CRBU) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment. Do analysts recommend CRBU or TVRD? Caribou Biosciences currently has a consensus price target of $6.67, indicating a potential upside of 167.31%. Tvardi Therapeutics has a consensus price target of $55.50, indicating a potential upside of 1,010.00%. Given Tvardi Therapeutics' higher probable upside, analysts clearly believe Tvardi Therapeutics is more favorable than Caribou Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Caribou Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50Tvardi Therapeutics 1 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.29 Which has more volatility & risk, CRBU or TVRD? Caribou Biosciences has a beta of 2.59, indicating that its stock price is 159% more volatile than the S&P 500. Comparatively, Tvardi Therapeutics has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500. Do insiders & institutionals believe in CRBU or TVRD? 77.5% of Caribou Biosciences shares are owned by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are owned by institutional investors. 8.3% of Caribou Biosciences shares are owned by company insiders. Comparatively, 3.1% of Tvardi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media prefer CRBU or TVRD? In the previous week, Tvardi Therapeutics had 2 more articles in the media than Caribou Biosciences. MarketBeat recorded 3 mentions for Tvardi Therapeutics and 1 mentions for Caribou Biosciences. Caribou Biosciences' average media sentiment score of 1.17 beat Tvardi Therapeutics' score of 0.46 indicating that Caribou Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Caribou Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tvardi Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is CRBU or TVRD more profitable? Tvardi Therapeutics has a net margin of -678.79% compared to Caribou Biosciences' net margin of -1,800.93%. Caribou Biosciences' return on equity of -62.35% beat Tvardi Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Caribou Biosciences-1,800.93% -62.35% -49.65% Tvardi Therapeutics -678.79%-565.83%-66.71% Which has better earnings & valuation, CRBU or TVRD? Tvardi Therapeutics has lower revenue, but higher earnings than Caribou Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCaribou Biosciences$9.12M25.46-$149.10M-$1.78-1.40Tvardi Therapeutics$7.14M6.57-$70.87MN/AN/A SummaryCaribou Biosciences beats Tvardi Therapeutics on 9 of the 13 factors compared between the two stocks. Get Tvardi Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVRD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TVRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TVRD vs. The Competition Export to ExcelMetricTvardi TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$46.90M$3.42B$6.16B$10.78BDividend YieldN/A2.26%5.71%4.83%P/E RatioN/A23.2829.7128.64Price / Sales6.57270.86500.63191.51Price / CashN/A45.1236.6160.64Price / Book-1.6610.4012.026.61Net Income-$70.87M-$52.62M$3.32B$276.75M7 Day Performance-24.01%2.06%1.57%2.09%1 Month Performance-86.50%10.79%6.19%2.67%1 Year PerformanceN/A13.69%61.23%33.58% Tvardi Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TVRDTvardi Therapeutics2.7462 of 5 stars$5.00-3.1%$55.50+1,010.0%N/A$46.90M$7.14M0.0080High Trading VolumeCRBUCaribou Biosciences2.8606 of 5 stars$2.63-1.5%$6.67+153.5%+30.2%$244.91M$9.99M-1.48100Positive NewsAnalyst ForecastGap UpOGIOrganigram Global0.8722 of 5 stars$1.82-3.7%N/A-4.9%$244.72M$117.47M0.00860LFCRLifecore Biomedical1.1585 of 5 stars$6.49-0.6%$8.00+23.3%+28.2%$243.15M$128.87M-4.95690ALTSALT5 Sigma0.3242 of 5 stars$1.95-11.0%N/A-18.5%$243.02M$12.53M0.00170Gap UpAVIRAtea Pharmaceuticals1.8054 of 5 stars$3.06-1.9%$6.00+96.1%-8.3%$242.84MN/A0.0070Analyst ForecastSGMTSagimet Biosciences3.1855 of 5 stars$7.36-2.5%$25.67+248.7%+29.7%$239.36M$2M-4.028Gap UpCRBPCorbus Pharmaceuticals4.2299 of 5 stars$19.32+1.4%$45.43+135.1%+4.8%$236.77MN/A-4.0640Analyst ForecastAnalyst RevisionHigh Trading VolumeHRTXHeron Therapeutics3.951 of 5 stars$1.29-0.8%$4.50+248.8%-33.9%$236.48M$144.29M-64.50300ENTAEnanta Pharmaceuticals4.0211 of 5 stars$11.01-3.3%$20.83+89.2%-16.3%$235.37M$67.64M-2.55160Analyst ForecastRNACCartesian Therapeutics1.9271 of 5 stars$9.01-4.4%$40.00+344.0%-59.4%$234.28M$38.91M0.0064Analyst Forecast Related Companies and Tools Related Companies Caribou Biosciences Alternatives Organigram Global Alternatives Lifecore Biomedical Alternatives ALT5 Sigma Alternatives Atea Pharmaceuticals Alternatives Sagimet Biosciences Alternatives Corbus Pharmaceuticals Alternatives Heron Therapeutics Alternatives Enanta Pharmaceuticals Alternatives Cartesian Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TVRD) was last updated on 10/24/2025 by MarketBeat.com Staff From Our PartnersWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredIt’s Time to Buy “the NVIDIA of Quantum Computing”Yahoo Finance wrote that investing in quantum computing could... "Lead to life-changing returns... and make...Brownstone Research | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredWhat Wall Street Won’t Say Out LoudDiscover the 7 key indicators before everyone else doesAmerican Alternative | SponsoredFree: The Crypto Summit That Could Change Your LifeFed cuts unleash crypto's next wave The smart money is already moving. This is your chance to see their car...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tvardi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tvardi Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TVRD Stock Alerts